Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma

Fellner, Susan K.; Reiberger, Thomas; Ulbrich, G.; Ferlitsch, Arnulf; Wacheck, Volker; Peck‐Radosavljevic, Markus

doi:10.1016/j.dld.2009.04.013

Cited by 30 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preclinical models have shown that antiangiogenic therapy suppressed viable CEPs and raised the number of apoptotic CECs [52][53][54][55][56]. Elevated CEC and CEP levels appeared in patients with HCC [57,58], and were associated with tumor aggressiveness or advanced stage [58][59][60].…”

Section: Circulating Endothelial Cells (Cecs) / Circulating Endothelimentioning

confidence: 99%

Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

Shao¹,

Hsu²,

Cheng

2013

Liver Cancer

View full text Add to dashboard Cite

Antiangiogenic therapy, especially treatment with sorafenib, is the primary treatment for patients with advanced hepatocellular carcinoma (HCC). However, the efficacy of such therapy is modest, with low objective response rates and limited prolongation of survival times. Several researchers have investigated predictive biomarkers to help identify patients who can benefit most from antiangiogenic therapy. The largest study on this topic to date was based on the pivotal phase III study of sorafenib (the SHARP study) and did not find any plasma markers that could predict the efficacy of sorafenib. Other studies based on single-arm phase II clinical trials found some potential predictive markers, such as early alpha-fetoprotein response, the serum insulin-like growth factor-1 level at baseline, and the volume transfer constants of dynamic contrast-enhanced magnetic resonance imaging. These findings require validation by further studies. Identifying predictive biomarkers of antiangiogenic therapy for HCC remains challenging and warrants further investigations.

show abstract

Section: Circulating Endothelial Cells (Cecs) / Circulating Endothelimentioning

confidence: 99%

Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

Shao¹,

Hsu²,

Cheng

2013

Liver Cancer

View full text Add to dashboard Cite

show abstract

“…Thus, an additional marker, CD133, has been suggested as a means of ensuring the identity of EPCs. CD133 is a precursor of an EC-like phenotype and has been applied in combination with CD34 and VEGFR2 to identify presumed CEPCs [19][20][21][22]. However, the CD34?CD133?VEGFR2?…”

Section: Characteristics Of Epcsmentioning

confidence: 98%

Circulating endothelial progenitor cell: a promising biomarker in clinical oncology

et al. 2014

Med Oncol

View full text Add to dashboard Cite

Human cancers are endowed with sustained vascularization capability, and their growth, invasion, and metastasis are vascularization dependent. Recently, accumulated body of evidence suggests that endothelial progenitor cells (EPCs) can support vasculogenesis and induce angiogenesis through paracrine mechanisms. In addition, numerous clinical studies have revealed the increase in the number of EPCs in the peripheral blood of cancer patients and demonstrated the correlation of circulating EPCs (CEPCs) with the clinical outcomes. This review highlights current enrichment procedures and methods for the detection of CEPCs and different biomarkers to identify CEPCs as well as the functions of EPCs in tumor vascularization. Furthermore, we systematically review available studies on the clinical relevance of CEPCs in cancer patients to explore the potential diagnostic and prognostic values of CEPCs. Although several contrasting results exist, CEPCs can conceivably serve as a promising biomarker for the early diagnosis, prognosis prediction, and treatment response indication in the future. Additionally, further well-designed clinical studies with larger sample size and unique, specific enumeration procedures are warranted to achieve further insight into the clinical implications of CEPCs.

show abstract

“…The grade of tumor differentiation and the tumor histological type are the universally accepted criteria used to classify HCC. A numerous meta-analysis showed significant correlation of tumor recurrence and poor tumor differentiation [5,6,9,12]. There is also clear evidence that the less differentiated tumor is, the higher the risk of vascular invasion to the surrounding liver tissue [19,25].…”

Section: Review Of Literaturementioning

confidence: 99%

“…Histologic information on tumor characteristic is available no sooner than at the time of the pathologic examination of the explanted liver. The needle biopsy could be implicated in selected casesbecausemany tumors are not suitable for biopsy and there is a risk for cancer cell seeding during the procedure [6,12,15,23].…”

Section: Review Of Literaturementioning

confidence: 99%

Hcc Angiogenic Propriety and Tumor Recurrence in Liver Transplant Recipients

Krawczyk¹

2015

Pharm Anal Acta

View full text Add to dashboard Cite

Objective: Clinic-pathologic characteristic of hepatocellular carcinoma are mostly accounting for the tumor recurrence after liver transplantation. It is assumed that tumor angiogenesis capability contributes to the rates of post-transplant relapse, as well. The aim of study was to evaluate the contribution of the circulating hematopoietic stem cells (HSCs); endothelial progenitor cells (EPCs) and serum vascular endothelial growth factor (VEGF) to the recurrence of HCC after liver transplantation. Methods:The study was carried out on 49 cirrhotic patients with HCC within the Milan criteria. They were transplanted in 2009 and followed-up for 54 months, so far. The rates of circulating HSCs and EPCs were assessed through a phenotypic analysis of 2 ml of fresh blood in a flow cytometer. Serum VEGF concentration was measured by enzyme-linked immunoassay (ELISA). Histopathology examination of the liver explants was performed for tumor characteristic. The data were analyzed with statistical tests.Results: There were 9 deaths related to the procedure. Of 40 remaining patients the tumor recurred in 6 (15%) prior to 36 months and then in 5 (12.5%) prior to 54 months of observation. The pre-transplant rates of circulating HSCs and EPCs were significantly higher in patients with tumor relapse; Chisq=17.25, p<0.001 and Chisq=13.96, p<0.001, respectively. The differences in the serum VEGF concentration were not significant in this group, however. Conclusion:Tumor angiogenesis capability should be considered as the predictive factor of tumor relapse after liver transplantation.

show abstract

Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma

Cited by 30 publications

References 32 publications

Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

Circulating endothelial progenitor cell: a promising biomarker in clinical oncology

Hcc Angiogenic Propriety and Tumor Recurrence in Liver Transplant Recipients

Contact Info

Product

Resources

About